Hofseth Biocare ASA: HBC IMMUNOLOGY COMPLETES IN VIVO DRUG LEAD STUDIES FOR PROSTATE CANCER TREATMENT

08 Oct 2024 08:45 CEST

Ålesund, Norway, 8 October 2024.

HBC Immunology (HBCI) is pleased to announce the successful completion of its
prostate cancer treatment xenograft studies with its lead peptide FT-002a in a
novel oral formulation in combination with standard of care hormonal-targeting
therapy. Oral FT-002a significantly augmented the anti-tumour activity of
enzalutamide (Xtandi(®)) the market-leading androgen receptor inhibitor, in
models of indolent and aggressive prostate cancers.

Prostate cancer remains the most diagnosed cancer in men. Whilst most cases do
not shorten life expectancy, advanced prostate cancer remains incurable. Hormone
therapy remains the cornerstone of treatment; however, tumours eventually find
ways of overcoming treatment and start to grow and spread. Co-therapies that can
reinvigorate cancer treatments can provide vital clinical avenues to enhance
tumour cell sensitivity, as well as reversing resistance to standard cancer
therapies.

Dr Bomi Framroze, Chief Executive Officer of HBCI explains: "The ability of
cancer to hack the iron metabolism pathways is an important driver of tumour
growth and spread, and a means by which cancers can overcome the effects of
treatment. Our lead peptide candidate, FT-002a, holds exciting potential to
enhance the effectiveness of cancer therapy and improve the health and wellness
of cancer patients."

Higher levels of iron are needed by cancer cells to support growth and spread.
In addition to elevated levels of tumour regression, FT-002a demonstrated a
significant decrease in biomarkers of free iron in prostate cancer tumour cells,
validating the proposed mode of action.

The combination of these promising results with the inherent safety profile of
peptidyl drugs means HBCI is well positioned to make an IND submission for its
oral co-therapy for prostate cancer treatment in Q4 2025.

For further information on HBC, please contact:
Dr Crawford Currie, Head of Medical R&D
Tel: +44 7968 195 497
cc@hofsethbiocare.com (mailto:cc@hofsethbiocare.com)

About HBC:
HBC is a Norwegian human and pet health ingredient supplier and an incubator for
new pharmaceutical drug leads, which are then developed by HBCI to enable the
clinical development of novel therapies. To date, the FT peptides, targeting
cancer, and MA-022, for asthma, have been transferred to HBCI for ongoing R&D
work. HBC retains 70% ownership of HBCI.

Research is ongoing to identify the individual elements within its ingredients
that modulate inflammation and the immune response with pre-clinical studies
ongoing in multiple clinics and university research labs. Lead clinical and pre-
clinical candidates are focused on developing an oral treatment for inflammatory
disease driven by eosinophils (a type of white blood cell). Clinical trial work
with full-spectrum omega salmon oil is ongoing to improve respiratory health in
individuals with allergic asthma and in urban populations exposed to significant
levels of pollution and has already shown beneficial effects on COVID recovery.

Other leads are focused on the protection of the Gastro-Intestinal (GI) system
against inflammation (including ulcerative colitis and the orphan condition
necrotizing enterocolitis) and the use of a special formula of soluble protein
hydrolysate (SPH, also known as ProGo(®)) as a Medical Food to help treat IBD
and Iron Deficiency Anemia.

The company is founded on the core values of sustainability, optimal utilization
of natural resources and full traceability. Through an innovative hydrolysis
technology, HBC can preserve the quality of the lipids, proteins and calcium
from fresh salmon off-cuts. HBC's headquarters are in Ålesund, Norway with
branches in Oslo, London, Zürich, New Jersey and Palo Alto.

HBC is listed on Oslo Børs with ticker "HBC". https://hofsethbiocare.com

This information is considered to be inside information pursuant to the EU
Market Abuse Regulation (MAR) and is subject to the disclosure requirements
pursuant to MAR article 17 and section 5-12 of the Norwegian Securities Trading
Act.

More information:
Access the news on Oslo Bors NewsWeb site